Dr Mark Linch is a Honorary Senior Lecturer at University College London (UCL) Cancer Institute, where he leads the Uro-oncology Biology Group, and a Consultant Medical Oncologist specialising in the treatment of prostate and bladder cancer at UCLH.
Dr Linch is currently Principal Investigator or Co-investigator in numerous clinical trials in prostate, bladder and penile cancer, both early and late phase. Dr Linch leads on a number of studies involving in depth profiling of patients’ cancers, looking for genetic, protein and immune cell changes that are associated with cancer. Through this work, Dr Linch hopes to be able to match individual patients with effective therapies, incorporate immunotherapy into routine clinical practice for urological malignancies and help develop novel therapies.